📇 Rhumatologue · REIMS CEDEX · (51) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
134.8 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
26
26 articles ont été cités au moins 26fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
3 314
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
175
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
43
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Institut Jean Godinot
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Return to work among self-employed breast cancer survivors from the CANTO cohort
2026ArticleScientific Reports
ATTITUDE - Addressing attrition in longitudinal cancer cohorts: an in-depth qualitative analysis of experiences and perspectives on participation in longitudinal studies among breast cancer survivors
2026ArticleBreast Cancer Research and Treatment
Improving CTVboost delineation after preoperative systemic therapy in breast cancer using deformable PET/CT registration
2026ArticleThe Breast
Melatonin supplementation for quality of life in older patients with advanced cancer: a randomized controlled trial
2025ArticleBMC Geriatrics
Working conditions associated with return to work 2 years after breast cancer: insights from a cohort study
2025ArticleBritish Journal of Cancer
Dose/Exposure Relationship of Exercise and Distant Recurrence in Primary Breast Cancer
2024ArticleJournal of Clinical Oncology
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
2024ArticleEuropean Journal of Cancer
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
2024ArticleBreast Cancer Research and Treatment
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
INSTITUT GODINOT
1 R DU GENERAL KOENIG BP 171, 51056 REIMS CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
European journal of cancer (Oxford, England : 1990) · 2018
British journal of cancer · 2019
Abstract Background Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses. Methods The kinetics of central nervous system (CNS) metastases (CNS metastasis-free survival, CNSM-FS) and subsequent patient’s prognosis (overall survival, OS) according to the molecular subtype were retrospectively assessed in 16703 MBC patients of the ESME nationwide multicentre MBC database (Kaplan–Meier method). Results CNS metastases occurred in 4118 patients (24.6%) (7.2% at MBC diagnosis and 17.5% later during follow-up). Tumours were HER2−/HR+ (45.3%), HER2+/HR+ (14.5%), HER2+/HR− (14.9%) and triple negative (25.4%). Median age at CNS metastasis diagnosis was 58.1 years (range: 22.8–92.0). The median CNSM-FS was 10.8 months (95% CI: 16.5–17.9) among patients who developed CNS metastases. Molecular subtype was independently associated with CNSM-FS (HR = 3.45, 95% CI: 3.18–3.75, triple-negative and HER2−/HR+ tumours). After a 30-month follow-up, median OS after CNS metastasis diagnosis was 7.9 months (95% CI: 7.2–8.4). OS was independently associated with subtypes: median OS was 18.9 months (HR = 0.57, 95% CI: 0.50–0.64) for HER2+/HR+ , 13.1 months (HR = 0.72, 95% CI: 0.65–0.81) for HER2+/HR−, 4.4 months (HR = 1.55, 95% CI: 1.42–1.69) for triple-negative and 7.1 months for HER2−/HR+ patients (p <0.0001). Conclusions Tumour molecular subtypes strongly impact incidence, kinetics and prognosis of CNS metastases in MBC patients. Clinical trial registration NCT03275311.
European journal of cancer (Oxford, England : 1990) · 2020
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Breast (Edinburgh, Scotland) · 2026 · Journal Article
Kemmeugne J, Gallay L, Morland D, Hotton J, et al.
Scientific reports · 2026 · Journal Article
Lopez C, Licaj I, Dumas A, Havas J, et al.
Breast cancer research and treatment · 2026 · Journal Article
Martin E, Chichua M, Chiodi CK, Zyumbileva P, et al.
Journal of the National Cancer Institute · 2025 · Clinical Trial
Presti D, Di Meglio A, Havas J, Pagliuca M, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · Journal Article
Soldato D, Michiels S, Havas J, Di Meglio A, et al.
European journal of cancer (Oxford, England : 1990) · 2024 · Journal Article
Roussot N, Constantin G, Desmoulins I, Bergeron A, et al.
Cancer medicine · 2023 · Journal Article
Ruiz de Azua G, Kousignian I, Vaz-Luis I, Di Meglio A, et al.
Journal of cancer survivorship : research and practice · 2023 · Journal Article
Caumette E, Di Meglio A, Vaz-Luis I, Charles C, et al.
JAMA network open · 2022 · Journal Article
Lambertini M, Massarotti C, Havas J, Pistilli B, et al.
JAMA network open · 2022 · Comparative Study
de Calbiac O, Lusque A, Mailliez A, Bachelot T, et al.
Reproductive biomedicine online · 2022 · Journal Article
Mangiardi-Veltin M, Sebbag C, Rousset-Jablonski C, Ray-Coquard I, et al.
BMC cancer · 2022 · Clinical Trial Protocol
Delrieu L, Hamy AS, Coussy F, Kassara A, et al.
European journal of cancer (Oxford, England : 1990) · 2022 · Clinical Trial, Phase II
Delaloge S, Dureau S, D'Hondt V, Desmoulins I, et al.
JAMA network open · 2022 · Journal Article
Charles C, Bardet A, Larive A, Gorwood P, et al.
Current oncology (Toronto, Ont.) · 2021 · Journal Article
Caumette E, Vaz-Luis I, Pinto S, Havas J, et al.
NPJ breast cancer · 2021 · Journal Article
Bortolini Silveira A, Bidard FC, Tanguy ML, Girard E, et al.
Breast (Edinburgh, Scotland) · 2021 · Journal Article
Saleh K, Carton M, Dieras V, Heudel PE, et al.
Therapeutic advances in medical oncology · 2020 · Journal Article
Sirieix J, Fraisse J, Mathoulin-Pelissier S, Leheurteur M, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020 · Journal Article
Pistilli B, Paci A, Ferreira AR, Di Meglio A, et al.
Angiogenesis · 2020 · Journal Article
Vasseur A, Cabel L, Tredan O, Chevrier M, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Journal Article
Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, et al.
Breast (Edinburgh, Scotland) · 2020 · Clinical Trial
Penault-Llorca F, Kwiatkowski F, Arnaud A, Levy C, et al.
European journal of cancer (Oxford, England : 1990) · 2020 · Journal Article
Pasquier D, Darlix A, Louvel G, Fraisse J, et al.
Acta dermato-venereologica · 2019 · Case Reports
Clapé A, Vanhaecke C, Durlach A, Bernard P, et al.
European journal of cancer (Oxford, England : 1990) · 2018 · Journal Article
Gobbini E, Ezzalfani M, Dieras V, Bachelot T, et al.
Breast cancer research : BCR · 2017 · Journal Article
Curtit E, Pivot X, Henriques J, Paget-Bailly S, et al.
European journal of cancer (Oxford, England : 1990) · 2017 · Clinical Trial, Phase III
Pivot X, Fumoleau P, Pierga JY, Delaloge S, et al.
NPJ breast cancer · 2017 · Journal Article
Pivot X, Romieu G, Fumoleau P, Rios M, et al.
Breast (Edinburgh, Scotland) · 2026 · Journal Article
Trédan O, Loirat D, Chabaud S, Toussaint P, et al.
BMC geriatrics · 2025 · Journal Article
Ginzac A, Bourbouloux E, Rivoirard R, Jouannaud C, et al.
Breast cancer research and treatment · 2024 · Journal Article
Ginzac A, Molnar I, Durando X, Motte Rouge T, et al.
BMC geriatrics · 2025 · Journal Article
Ginzac A, Bourbouloux E, Rivoirard R, Jouannaud C, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · Journal Article
Sandoval JL, Franzoi MA, di Meglio A, Ferreira AR, et al.
Journal of the National Cancer Institute · 2023 · Journal Article
Balazard F, Bertaut A, Bordet É, Mulard S, et al.
Journal of the National Comprehensive Cancer Network : JNCCN · 2026 · Journal Article
Lapidari P, Lustberg MB, Havas J, Pagliuca M, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · Journal Article
Martin S, Fritsch A, Jouannaud C, Martin-Babau J, et al.
British journal of cancer · 2026 · Journal Article
Ruiz de Azua G, Licaj I, Pinto S, Havas J, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · Journal Article
Martin S, Fritsch A, Jouannaud C, Martin-Babau J, et al.
The oncologist · 2023 · Journal Article
Le Du F, Carton M, Bachelot T, Saghatchian M, et al.
European journal of cancer (Oxford, England : 1990) · 2023 · Journal Article
Grinda T, Antoine A, Jacot W, Cottu PH, et al.
British journal of cancer · 2022 · Journal Article
Baker JL, Di Meglio A, Gbenou AS, El Mouhebb M, et al.
Scientific reports · 2020 · Journal Article
Delrieu L, Jacquet E, Segura-Ferlay C, Blanc E, et al.
Case reports in oncology · 2021 · Case Reports
Invernizzi C, Gaultier V, Guilbert P, Jouannaud C, et al.
Oncotarget · 2016 · Journal Article
Cox DG, Curtit E, Romieu G, Fumoleau P, et al.
Case reports in oncology · 2021 · Case Reports
Invernizzi C, Gaultier V, Guilbert P, Jouannaud C, et al.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · Multicenter Study
Di Meglio A, Charles C, Martin E, Havas J, et al.
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
Abstract Background Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combi
Additional file 1: of Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
Table S1. List of 94 variants associated with risk, involved in the 94-SNP risk score (identification and characteristics of variants). (XLS 41 kb)
Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
Background and Aims:Because of its low prevalence, metastatic breast cancer (MBC) in males is managed based on clinical experience with women. Using a real-life database, we aim to provide a comprehensive analysis of mal
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
Abstract Background Genome-wide association studies (GWAS) have to date identified 94 genetic variants (single nucleotide polymorphisms (SNPs)) associated with risk of developing breast cancer. A score based on the combi
Additional file 1: of Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
Table S1. List of 94 variants associated with risk, involved in the 94-SNP risk score (identification and characteristics of variants). (XLS 41 kb)
Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME)
Background and Aims:Because of its low prevalence, metastatic breast cancer (MBC) in males is managed based on clinical experience with women. Using a real-life database, we aim to provide a comprehensive analysis of mal
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
Clinical breast cancer · 2023 · Clinical Trial, Phase III
Pivot X, Spano JP, Espie M, Jouannaud C, et al.
European journal of cancer (Oxford, England : 1990) · 2019 · Clinical Trial, Phase III
Huober J, Holmes E, Baselga J, de Azambuja E, et al.
Lancet (London, England) · 2019 · Clinical Trial, Phase III
Pivot X, Romieu G, Debled M, Pierga JY, et al.
Cancer · 2023 · Journal Article
Licaj I, Coquan E, Dabakuyo-Yonli TS, Dauchy S, et al.
Breast (Edinburgh, Scotland) · 2021 · Journal Article
Lapidari P, Gbenou A, Havas J, Martin E, et al.
British journal of cancer · 2019 · Journal Article
Darlix A, Louvel G, Fraisse J, Jacot W, et al.
Breast (Edinburgh, Scotland) · 2021 · Journal Article
Annonay M, Gauquelin L, Geiss R, Ung M, et al.